Key Takeaways:
Immunic Inc. (NASDAQ:IMUX) secured $200 million in new financing to advance its pivotal Phase 3 trials for vidofludimus calcium, an oral drug for relapsing multiple sclerosis (RMS), with top-line data from the studies expected by the end of 2026.
"This highly successful transaction signals investors' continued confidence in Immunic and has provided the resources we need to advance our programs through key milestones and to continue our transition into a commercial-stage company,” Daniel Vitt, PhD, Chief Executive Officer of Immunic, said in a statement.
The oversubscribed private placement, led by existing investor BVF Partners L.P., provides an initial $200 million in gross proceeds with the potential for up to an additional $200 million. The company reported cash and cash equivalents of $186.6 million as of March 31, 2026, which it expects will fund operations into late 2027, through the completion of the Phase 3 RMS trials and its planned New Drug Application (NDA) submission.
The financing de-risks Immunic's path toward potential commercialization of vidofludimus calcium, a novel dual-action therapy combining neuroprotective and anti-inflammatory effects. If successful, the drug would enter a global multiple sclerosis market projected to exceed $30 billion by the early 2030s, with a potential U.S. approval targeted for 2028.
Immunic is advancing its twin Phase 3 trials, ENSURE-1 and ENSURE-2, for vidofludimus calcium in RMS. Following the anticipated data readout by year-end 2026, the company plans to file an NDA with the U.S. Food and Drug Administration in mid-2027. Further expanding the drug's potential, Immunic also plans to initiate a confirmatory Phase 3 program for vidofludimus calcium in primary progressive multiple sclerosis (PPMS) later this year, a study expected to take approximately 3.5 to 4 years to complete.
In anticipation of becoming a commercial-stage company, Immunic has made several key leadership appointments. The company named Dr. Michael A. Panzara, a neurologist and biopharmaceutical executive with a track record in MS therapies, as its new Chief Medical Officer. It also appointed Jon Congleton to its board and elevated Simona Skerjanec to interim Chairperson, moves intended to position the company for its late-stage development and potential launch.
For the first quarter ended March 31, 2026, Immunic reported a net loss of approximately $32.6 million, or $1.08 per share. Research and Development (R&D) expenses increased to $25.6 million from $21.5 million in the prior-year period, driven by costs related to the vidofludimus calcium program. General and Administrative (G&A) expenses were $7.6 million. The company also effected a 1-for-10 reverse stock split in April 2026 to regain compliance with Nasdaq's minimum bid price requirement.
This article is for informational purposes only and does not constitute investment advice.
